A breakthrough study published in Clinical Cancer Research describes a minimally invasive method for interrogating mechanisms of therapeutic resistance in metastatic castration-resistant prostate cancer.
Scientists from the Vancouver Prostate Centre lead by Dr. Kim Chi, along with their international collaborators, have performed the largest cohort study of patients with advanced prostate cancer to look for prostate cancer-specific mutations in circulating cell-free DNA (cfDNA) (i.e. from blood samples). It is the first study to tie such results to clinical outcomes.
VPC researchers are further testing their findings in several clinical trials. If the trials show a strong connection between the genetic profile and treatment, the blood test will hopefully roll out to clinical use.